MAPT and Cognitive impairment: Intracerebroventricularly injection of STZ, a glucosamine-nitrosourea chemical compound, can lead to impairments of cerebral glucose and energy metabolism, increase of acetylcholinesterase (AChE) activity, hyperphosphorylation of tau proteins, Aβ accumulation (Biasibetti et al., 2013; Halawany et al., 2017), reduction of hippocampal synaptic transmission, oxidative stress and inflammation (Shoham et al., 2007; Salkovic-Petrisic et al., 2011), which finally lead to cognitive deficits (Abbasi et al., 2018).